In quick succession after the recent IMPACTT collaboration project to develop a COVID-19 biomarker panel, Oncimmune has signed its first commercial agreement with Cedars-Sinai to provide antibody profiling of its samples. Cedars-Sinai is a leading US hospital organisation, and Oncimmune will be paid on commercial terms to profile the antibodies from samples taken at Cedar-Sinai Hospitals. This first commercial contract is months ahead of our expectations and gives an early look of the strong
13 Oct 2020
Cedars-Sinai win; early look into COVID-19 demand
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cedars-Sinai win; early look into COVID-19 demand
Oncimmune Holdings Plc (ONC:LON) | 27.6 -0.4 (-5.2%) | Mkt Cap: 20.5m
- Published:
13 Oct 2020 -
Author:
Edward Thomason -
Pages:
3
In quick succession after the recent IMPACTT collaboration project to develop a COVID-19 biomarker panel, Oncimmune has signed its first commercial agreement with Cedars-Sinai to provide antibody profiling of its samples. Cedars-Sinai is a leading US hospital organisation, and Oncimmune will be paid on commercial terms to profile the antibodies from samples taken at Cedar-Sinai Hospitals. This first commercial contract is months ahead of our expectations and gives an early look of the strong